New Immune-Guiding drug shows promise in advanced prostate cancer trial

NCT ID NCT04898634

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug, JNJ-78278343, that helps the body's immune T-cells find and attack prostate cancer cells. It involves 216 men with advanced prostate cancer that has spread. The main goals are to find the safest and most effective dose and to monitor side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS

Contacts and locations

Locations

APHM Hopital Timone

Marseille, 13005, France
Antoni van Leeuwenhoek

Amsterdam, 1066 CX, Netherlands
Centre Leon Berard

Lyon, 69373, France
Chongqing University Cancer Hospital

Chongqing, 400030, China
Columbia University Medical Center Herbert Irving Pavilion

New York, New York, 10032, United States
Erasmus MC

Rotterdam, 3015 GD, Netherlands
First Affiliated Hospital Of Wenzhou Medical College

Wenzhou, 325399, China
Hosp Univ Fund Jimenez Diaz

Madrid, 28040, Spain
Hosp Univ Hm Sanchinarro

Madrid, 28050, Spain
Hosp Virgen de La Victoria

Málaga, 29010, Spain
Institut Gustave Roussy

Villejuif, 94800, France
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
National Cancer Center Hospital East

Kashiwa, 277 8577, Japan
Peking University Third Hospital

Beijing, 100191, China
Sun Yat Sen University Cancer Center

Guangzhou, 510710, China
University of Washington

Seattle, Washington, 98195-9472, United States
Yokohama City University Medical Center

Yokohama, 232 0024, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.